Geoffrey Guy - GW Pharmaceuticals Executive Chairman of the Board

Chairman

Dr. Geoffrey W. Guy is Executive Chairman of the Board of GW Pharmaceuticals PLC. Dr. Guy has over 30 years of experience in medical research and global drug development, most recently as Chairman and Chief Executive of Ethical Holdings plc, a Nasdaqquoted drug delivery company, which he founded in 1985 and led to its Nasdaq listing in 1993. He also founded Phytopharm plc in 1989, of which he was Chairman until 1997. Dr. Guy was the physician in charge of over 200 clinical studies including first dose in man, pharmacokinetics, pharmacodynamics, doseranging, controlled clinical trials and large scale multicentered studies and clinical surveys. He is also an author on numerous scientific publications and has contributed to six books
Age 59
Phone(44) 1223 235667
Webwww.gwpharm.com
Guy was appointed as Visiting Professor in the School of Science and Medicine at the University of Buckingham in July 2011. He also received the "Deloitte Director of the Year Award in Pharmaceuticals and Healthcare" in 2011. Dr Guy holds a BSc in pharmacology from the University of London, an MBBS at St Bartholomew’s Hospital, an MRCS Eng and LRCP London, an LMSSA Society of Apothecaries and a Diploma of Pharmaceutical Medicine from the Royal Colleges of Physicians.

GW Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (3.55) % which means that it has lost $3.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.92) %, meaning that it created substantial loss on money invested by shareholders. GW Pharmaceuticals' management efficiency ratios could be used to measure how well GW Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 43.64 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. GW Pharmaceuticals Plc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GW Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, GW Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GW Pharmaceuticals Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GWPH to invest in growth at high rates of return. When we think about GW Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

CHAIRMAN Age

Gary RollinsMarine Products
76
William DaleyBank Of New
70
Curtis ArledgeBank Of New
49
Kenneth HicksAcademy Sports OutdoorsInc
72
Ying LeeIntegrated Media Technology
61
David NetherwayAcademy Sports OutdoorsInc
N/A
Randall RollinsMarine Products
86
Hani KablawiBank Of New
52
Brian SheaBank Of New
55
Gerald HassellBank Of New
64
Thomas GibbonsBank Of New
64
Charles ScharfBank Of New
52
Joseph EchevarriaBank Of New
64
Robin VinceBank Of New
52
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. Gw Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 1161 people. GW Pharmaceuticals Plc (GWPH) is traded on NASDAQ Exchange in USA and employs 1,161 people.

Management Performance

GW Pharmaceuticals Plc Leadership Team

Elected by the shareholders, the GW Pharmaceuticals' board of directors comprises two types of representatives: GW Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GWPH. The board's role is to monitor GW Pharmaceuticals' management team and ensure that shareholders' interests are well served. GW Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GW Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Waldegrave, Non-Executive Independent Director
Christopher Tovey, COO, Executive Director
Thomas Lynch, Non-Executive Independent Director
Catherine Mackey, Non-Executive Independent Director
Justin Gover, CEO, Director
Geoffrey Guy, Executive Chairman of the Board
James Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
Julian Gangolli, Executive Director
Alicia Secor, Non-Executive Independent Director
Adam George, CFO, Company Secretary, Director
Cabot Brown, Non-Executive Independent Director
Stephen Wright, Research & Development Director, Executive Director
Darren Cline, Chief Commercial Officer, U.S.

GWPH Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GW Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GW Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GW Pharmaceuticals' short interest history, or implied volatility extrapolated from GW Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Consideration for investing in GWPH Stock

If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Directory
Find actively traded commodities issued by global exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes